Sr. Data Platform Engineer - Computer System Validator
Recursion · London, United Kingdom · Software Engineering
About this role
Recursion is hiring a senior-level Data Engineer based in London, United Kingdom. The posting calls out experience with GCP, Elasticsearch, Data Structures, Configuration Management. Compensation is listed at £75,900–£101,900 per year.
- Role
- Data Engineer
- Function
- data engineering
- Level
- senior
- Track
- Individual contributor
- Employment
- Full-time
- Location
- London, United Kingdom
- Department
- Software Engineering
More roles at Recursion
Job description
from Recursion careersYour work will change lives. Including your own.
Recursion is a leading, clinical-stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.
In this role, you will:
- Build, scale, and operate in a validated data platform. You will be a member of the platform team responsible for building, operating, and tuning a data platform with petabyte scale data, and maintaining a GxP-compliant data platform for clinical data. These platforms allow our users to discover and query across the breadth of our data at Recursion, which includes a chemistry library of billions of compounds, cellular microscopy images taken in millions of different experimental contexts, and millions of assay results, all supporting Recursion’s drug discovery.